格隆汇10月10日丨药明康德(02359.HK)发布公告，2025年10月10日，根据5亿美元于2025年到期的零息 有担保可转换债券而转换及发行1806.46万股H股。 ...

证券之星消息，10月10日医疗服务板块较上一交易日下跌4.01%，药明康德领跌。当日上证指数报收于 3897.03，下跌0.94%。深证成指报收于13355.42，下跌2.7%。医疗服务板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流出12.75亿元，游资资金净流入2.43亿元，散户资金 净流入10.32亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002044 | 美年健康 | 3910.83万 | 10.85% | -198.32万 | -0.55% | -3712.51万 | -10.30% | | 688238 和元生物 | | 2910.07万 | 10.43% | -28.06万 | -0.10% | -2882.01万 ...

智通财经APP讯，药明康德(02359)发布公告，于2025年10月10日，根据5亿美元于2025年到期的零息有 担保可转换债券而转换及发行1806.46万股H股。 ...

格隆汇10月10日丨药明康德(02359.HK)宣布，董事会将于2025年10月24日（星期五）召开董事会会议， 以考虑及批准（其中包括）集团截至2025年9月30日止九个月的第三季业绩及其发布。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： 呈交日期： 2025年10月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | A. 已發行股份或庫存股份變 ...

無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2025年10月24日（星期五）召開董事會會議，以考 慮及批准（其中包括）本集團截至2025年9月30日止九個月之第三季業績及其發佈。 香港交易及結算所有限公司及香港聯合交易所有限公司對本 公告 的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本 公告 全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 董事會會議召開日期 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年10月10日 截至本公告日期，董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生；非 執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 ...

Market Overview - The A-share market experienced a day of volatility and adjustment, with all three major indices closing down: Shanghai Composite Index fell by 0.94%, Shenzhen Component Index dropped by 2.70%, and ChiNext Index decreased by 4.55% [1][2] - The total market turnover was 2.53 trillion yuan, a decrease of 137.7 billion yuan compared to the previous day [2] Sector Performance - Gas and coal sectors showed gains, while semiconductor, battery, and precious metals sectors faced significant declines, with semiconductor funds seeing an outflow exceeding 20 billion yuan [2][3] - Notable individual stock movements included CATL and Sanhua Intelligent Control, both experiencing fund outflows over 2 billion yuan, while ZTE Corporation saw a rise of over 4% [4] Precious Metals - The price of spot gold fell below the 4000 USD mark, closing at 3965 USD per ounce, leading to a decline in A-share precious metal stocks, with several stocks like Western Gold and Chifeng Jilong Gold dropping over 5% [8][10] - Analysts suggest that persistent inflation data in the U.S. could lead to a stronger dollar and higher real interest rates, reducing gold's attractiveness [11] Investment Sentiment - The first three quarters of the year saw significant gains in major indices: Shanghai Composite Index up 15.84%, Shenzhen Component Index up 29.88%, and ChiNext Index and Sci-Tech 50 Index both up 51.20% [14] - The best-performing sectors included non-ferrous metals, hardware equipment, and semiconductors, with emerging concepts like AI and controlled nuclear fusion gaining traction [14] - Market sentiment indicates a cautious outlook for the fourth quarter, with a potential shift in investment focus from technology to traditional sectors like real estate and machinery [15]

本次减持对药明康德的财报将产生立竿见影的效果。公司称，出售的药明合联股票在账面上列为"长期 股权投资"。经公司财务部门初步测算，本次出售药明合联的投资净收益对公司2025年度税后净利润的 影响约为16.79亿元，占公司2024年归属净利润的比例超过10%。 药明康德还表示，截至此次出售，2025年累计出售药明合联股票的投资净收益对公司2025年税后净利润 的影响约为43.51亿元。 港股药明合联再次遭到股东药明康德（603259）的减持。药明康德10月9日晚称已减持药明合联3030万 股，套现逾23亿港元。截至发稿，药明康德大跌逾7%，药明合联大跌逾6%。 药明康德公告，公司于10月8日通过大宗交易方式，出售了其间接控股子公司所持有的药明合联3030万 股，约占其总股本的2.47%。此次交易成交金额达到约23.46亿港元（不含交易费用）。 记者注意到，最近一年药明康德已多次减持药明合联。2024年11月、2025年1月药明康德分别减持药明 合联3600万股和5000万股，累计成交金额约24.26亿港元；2025年4月，公司继续减持药明合联5080万 股，成交金额约21.78亿港元。如果加上本次减持，最近一年药 ...

Market Performance - The Hong Kong stock market continued its decline, with notable drops in several biotech companies [1] - Innovent Biologics (09969) fell by 11.19%, closing at 14.760, with a market capitalization of 26.021 billion and a year-to-date increase of 141.18% [2] - Rongchang Biologics (09995) decreased by 10.22%, with a latest price of 95.350 and a total market value of 53.74 billion, reflecting a year-to-date increase of 562.15% [2] - WuXi AppTec (02268) and WuXi Biologics (02269) experienced declines of 5.68% and 5.32%, respectively, with market caps of 89.818 billion and 1585.28 billion [2] - Other companies such as Fuhong Hanlin (02696) and Kelun-Biotech (06990) also saw declines of over 4% [1][2] Company Highlights - Innovent Biologics has shown a significant year-to-date performance increase of 141.18% despite the recent drop [2] - Rongchang Biologics has the highest year-to-date increase among the listed companies at 562.15% [2] - WuXi Biologics and WuXi AppTec have maintained strong year-to-date increases of 120.84% and 138.50%, respectively [2] - Fuhong Hanlin and Kelun-Biotech also reported substantial year-to-date increases of 205.49% and 199.33% [2]

Core Insights - The article emphasizes the importance of both performance and institutional recognition in evaluating investment opportunities, particularly focusing on companies like SMIC and WuXi AppTec, which have shown promising earnings forecasts and institutional holdings [1] Group 1: SMIC - SMIC's Q3 earnings forecast indicates a revenue increase of 12%-15% year-on-year and a net profit increase of 8%-10%, exceeding market expectations of a 5% net profit growth [3] - The growth is attributed to the full capacity utilization of the 28nm mature process, which now accounts for 42% of total revenue, up 3 percentage points from Q2 [3] - Institutional holdings have increased, with public funds adding 120 million shares and social security funds increasing by 20 million shares, indicating long-term confidence from institutional investors [3] Group 2: WuXi AppTec - WuXi AppTec's Q3 forecast shows a revenue increase of 25%-28% year-on-year and a net profit increase of 30%-32%, with growth rates faster than Q2 [3] - The core driver of this growth is an increase in outsourcing orders from global pharmaceutical companies, with North American business up 22%, European business up 27%, and domestic innovative drug services up 35% [3] - Northbound capital has increased holdings by 80 million shares, bringing the total holding ratio to 12%, with notable fund managers maintaining or slightly increasing their positions, reflecting confidence in long-term growth [3] Group 3: CATL - CATL's Q3 earnings forecast shows a revenue increase of 30%-33% year-on-year and a net profit increase of 28%-30%, surpassing market expectations of 25% [4] - The contribution from the Kirin battery has begun, accounting for 8% of total revenue and showing a 150% increase from Q2, with European business growing by 40% [4] - Institutional holdings have also increased, with insurance funds adding 50 million shares, and partnerships with companies like Li Auto and NIO indicating strong industry support [4] Group 4: Kweichow Moutai - Kweichow Moutai's Q3 forecast indicates a revenue increase of 10%-12% year-on-year and a net profit increase of 11%-13%, consistent with Q2 growth rates [4] - A notable detail is the 25% increase in direct sales revenue, which now accounts for 38% of total revenue, suggesting potential for improved profit margins [4] - Institutional holdings remain stable, with social security funds and insurance capital maintaining their positions, indicating a solid foundation for long-term investment [4] Group 5: Overall Investment Sentiment - The article concludes that for long-term investors, the sustainability of growth rates and the recognition from professional funds are crucial indicators, with the highlighted companies meeting these criteria [5]